Abstract
Background & aim: Cyclophosphamide (CP) is an immunosuppressive medication which is primarily used to manage and treatt of neoplasms, including breast cancer, lymphoma and Leukemia. CP as well possesses many side effects, including hepatotoxicity which leads to mitochondrial oxidative stress, cell death and hepatic necrosis. Empagliflozin (EMPA) is a Sodium-glucose cotransporter-2 inhibitor ...

This publication has 24 references indexed in Scilit: